Search Result

Results for "

Acute myelogenous leukemia

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (1) Akt (2) Apoptosis (15) Bcl-2 Family (1) Bcr-Abl (1) c-Kit (5) CDK (1) Dihydroorotate Dehydrogenase (2) DNA/RNA Synthesis (4) Drug Metabolite (3) E1/E2/E3 Enzyme (1) Epigenetic Reader Domain (1) Eukaryotic Initiation Factor (eIF) (2) FGFR (4) FLT3 (11) Glutathione Peroxidase (2) GSK-3 (2) HDAC (1) HIV (1) IFNAR (5) IKZF Family (1) Interleukin Related (2) Isocitrate Dehydrogenase (IDH) (1) Isotope-Labeled Compounds (1) JAK (3) Ligands for Target Protein for PROTAC (1) LPL Receptor (2) Mitochondrial Metabolism (1) Molecular Glues (1) mTOR (1) Nucleoside Antimetabolite/Analog (3) P-glycoprotein (3) PDGFR (5) Phosphatase (1) PI3K (1) Pim (1) PROTACs (1) Reactive Oxygen Species (ROS) (2) Reference Standards (5) Src (3) STAT (3) Tim3 (1) TNF Receptor (5)
By Research Areas:	Cancer (42) Cardiovascular Disease (3) Infection (2) Inflammation/Immunology (12) Metabolic Disease (4) Neurological Disease (1)
Oligonucleotides:	CpG ODNs (2)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: BMI1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15255

Zosuquidar 15+ Cited Publications RS 33295-198; LY-335979	P-glycoprotein	Cancer
Zosuquidar (LY335979) is a P-glycoprotein (P-gp) inhibitor (K_i=59 nM). Zosuquidar shows anti-tumor activities, and can be used in acute myelogenous leukemia (AML) research .

HY-112654

GCN2iB Maximum Cited Publications 60 Publications Verification	Eukaryotic Initiation Factor (eIF) Glutathione Peroxidase	Cardiovascular Disease Metabolic Disease Cancer
GCN2iB is an ATP-competitive, selective GCN2 inhibitor with an IC₅₀ of 2.4 nM. GCN2iB inhibits the activation of the GCN2 pathway and upregulates GPX4. GCN2iB enhances the anticancer effect of ASNase against acute lymphoblastic leukemia. GCN2iB increases left ventricular ejection fraction, while reducing fasting blood glucose and myocardial fibrosis. GCN2iB can be used in research related to acute lymphoblastic leukemia, acute myeloid leukemia and diabetic cardiomyopathy .

HY-50671

Zosuquidar trihydrochloride 15+ Cited Publications RS 33295-198 trihydrochloride; LY-335979 trihydrochloride	P-glycoprotein	Cancer
Zosuquidar (LY335979) trihydrochloride is a P-glycoprotein (P-gp) inhibitor (K_i=59 nM). Zosuquidar trihydrochloride shows anti-tumor activities, and can be used in acute myelogenous leukemia (AML) research .

HY-112852

TL02-59 5+ Cited Publications	Src Apoptosis	Cancer
TL02-59 is an orally active, selective Src-family kinase Fgr inhibitor with an IC₅₀ of 0.03 nM. TL02-59 inhibits Lyn and Hck with IC₅₀s of 0.1 nM and 160 nM, respectively. TL02-59 potently suppresses acute myelogenous leukemia (AML) cell growth .

HY-150725

ODN 1585	IFNAR TNF Receptor	Infection Inflammation/Immunology Cancer
ODN 1585 is a potent inducer of IFN and TNFα production. ODN 1585 is a potent stimulator of NK (natural killer) function. ODN 1585 increases CD8+ T-cell function, including the CD8+ T cell-mediated production of IFN-γ. ODN 1585 induces regression of established melanomas in mice. ODN 1585 can confer complete protection against malaria in mice. ODN 1585 can be used for acute myelogenous leukemia (AML) and malaria research. ODN 1585 can be used as a vaccine adjuvant .

HY-10202

Tandutinib 5 Publications Verification MLN518; CT53518	FLT3 c-Kit PDGFR Apoptosis	Cancer
Tandutinib (MLN518) is a potent and selective inhibitor of the FLT3 with an IC₅₀ of 0.22 μM, and also inhibits c-Kit and PDGFR with IC₅₀s of 0.17 μM and 0.20 μM, respectively. Tandutinib can be used for acute myelogenous leukemia (AML) . Tandutinib has the ability to cross the blood-brain barrier .

HY-13660

Mocravimod hydrochloride 2 Publications Verification KRP-203	LPL Receptor Reactive Oxygen Species (ROS) Akt GSK-3 JAK STAT	Metabolic Disease Inflammation/Immunology Cancer
Mocravimod (hydrochloride) is an orally active sphingosine-1-phosphate receptor (S1PR) modulator that blocks the signal required by T cells to egress from lymph nodes and other lymphoid organs. Mocravimod (hydrochloride) preferentially binds to S1PR1 over S1PR2 and S1PR3 in cardiomyocytes. Mocravimod (hydrochloride) significantly lowered the concentration of reactive oxygen species (ROS), prevented mitochondrial permeability transition pore opening, boosted mitochondrial membrane potential (MMP), and increased phosphorylation of AKT, EKR, GSK-3β, JAK2, and STAT3. Mocravimod (hydrochloride) retains T cell effector function. Mocravimod (hydrochloride) can be used for the study of acute myelogenous leukemia, diabetes and Myocardial Ischemia-Reperfusion Injury (MIRI) .

HY-109038

Mocravimod 2 Publications Verification KRP-203 free base	LPL Receptor Reactive Oxygen Species (ROS) Mitochondrial Metabolism Akt GSK-3 JAK STAT	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Mocravimod (KRP-203 free base) is a sphingosine-1-phosphate receptor (S1PR) modulator that blocks the signal required by T cells to egress from lymph nodes and other lymphoid organs. Mocravimod preferentially binds to S1PR1 over S1PR2 and S1PR3 in cardiomyocytes. Mocravimod significantly lowered the concentration of reactive oxygen species (ROS), prevented mitochondrial permeability transition pore opening, boosted mitochondrial membrane potential (MMP), and increased phosphorylation of AKT, EKR, GSK-3β, JAK2, and STAT3. Mocravimod retains T cell effector function. Mocravimod can be used for the study of acute myelogenous leukemia, diabetes and Myocardial Ischemia-Reperfusion Injury (MIRI) .

HY-12475

Mutant IDH1-IN-1 2 Publications Verification Agios 135	Isocitrate Dehydrogenase (IDH)	Cancer
Mutant IDH1-IN-1 (Agios 135) is a selective mutant IDH1 inhibitor with activity against both IDH1 ^R132H and IDH1 ^R132C. Mutant IDH1-IN-1 reduces the level of 2-hydroxyglutarate (2-HG), stabilizes mutant IDH1 protein, and restores blocked monocyte differentiation. Mutant IDH1-IN-1 can be used in tumor-related research .

HY-145723

MAX-40279 1 Publications Verification	FLT3 FGFR	Inflammation/Immunology Cancer
MAX-40279 is a dual and orally active inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 is also effective against the FLT3 mutants such as FLT3 ^D835Y, suggesting that it can overcome resistance to Quizartinib (HY-13001) and Sorafenib (HY-10201). MAX-40279 inhibits NDRG1 phosphorylation at Ser330 and suppresses endothelial-to-mesenchymal transition (EndMT). MAX-40279 can be used for the research of acute myelogenous leukemia (AML) .

HY-16445B

CNDAC hydrochloride	Nucleoside Antimetabolite/Analog Drug Metabolite Apoptosis DNA/RNA Synthesis	Cancer
CNDAC hydrochloride is a metabolite of the orally active agent Sapacitabine (HY-16445), and a nucleoside analog. CNDAC hydrochloride induces DNA damage and apoptosis .

HY-150725C

ODN 1585 sodium	TNF Receptor IFNAR	Infection Inflammation/Immunology Cancer
ODN 1585 sodium is a potent inducer of IFN and TNFα production. ODN 1585 sodium is a potent stimulator of NK (natural killer) function. ODN 1585 sodium increases CD8+ T-cell function, including the CD8+ T cell-mediated production of IFN-γ. ODN 1585 sodium induces regression of established melanomas in mice. ODN 1585 sodium can confer complete protection against malaria in mice. ODN 1585 sodium can be used for acute myelogenous leukemia (AML) and malaria research. ODN 1585 sodium can be used as a vaccine adjuvant .

HY-P990786

Anti-FLT3 Antibody (AGS62P)	FLT3 ADC Antibody	Cancer
Anti-FLT3 Antibody (AGS62P) is an ADC antibody targeting FLT3, and can be used for acute myelogenous leukemia .

HY-162608

PROTAC JAK1 degrader 1	PROTACs JAK STAT	Cancer
PROTAC JAK1 degrader 1 is a JAK1 PROTAC degrader with a DC₅₀ of 214 nM and an IC₅₀ of 5.2 nM. PROTAC JAK1 degrader 1 inhibits the downstream JAK-STAT signaling pathway by degrading JAK1. PROTAC JAK1 degrader 1 exhibits antiproliferative activity in cells. PROTAC JAK1 degrader 1 can be used for research on leukemia .

HY-P4122

TAT (47-57), FAM-labeled	HIV	Others
TAT (47-57), FAM-labeled is a 5(6)-Carboxyfluorescein (HY-15940)-labeled TAT (HY-P0281). TAT (YGRKKRRQRRR) is derived from the transactivator of transcription (TAT) of human immunodeficiency virus-1 (HIV-1) and is a cell-penetrating peptide .

HY-10202A

Tandutinib hydrochloride 5 Publications Verification MLN518 hydrochloride; CT53518 hydrochloride	FLT3 c-Kit PDGFR Apoptosis	Cancer
Tandutinib hydrochloride (MLN518 hydrochloride) is a potent and selective inhibitor of the FLT3 with an IC₅₀ of 0.22 μM, and also inhibits c-Kit and PDGFR with IC₅₀s of 0.17 μM and 0.20 μM, respectively. Tandutinib hydrochloride can be used for acute myelogenous leukemia (AML) . Tandutinib hydrochloride has the ability to cross the blood-brain barrier .

HY-148602

KH-4-43 1 Publications Verification	E1/E2/E3 Enzyme	Cancer
KH-4-43 is an inhibitor of E3 CRL4. KH-4-43 inhibits E3 CRL4's core ligase complex and exhibits anticancer activity. KH-4-43 has a binding K_d to E3 ROC1-CUL4A CTD or the highly related ROC1-CUL1 CTD at 83 nM or 9.4 μM, respectively .

HY-159884

MG-T-19	Tim3 TNF Receptor IFNAR	Cancer
MG-T-19 is an effective TIM-3 inhibitor that can suppress the interaction of TIM-3 with PtdSer, CEACAM1, and Gal-9. MG-T-19 can increase the production of tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ) in peripheral blood mononuclear cells (PBMCs) from healthy donors, and enhance the ability of PBMCs to inhibit the proliferation of Kasumi-1 cells (an acute myelogenous leukemia cell line) .

HY-123141

K00135	Pim	Cancer
K00135 is a potent and selective inhibitor of PIM kinases. K00135 inhibits survival and clonogenic growth of acute leukemia cells. K00135 inhibits the phosphorylation of PIM downstream targets .

HY-13743

Roquinimex Linomide; FCF89; ABR212616	TNF Receptor Interleukin Related IFNAR	Neurological Disease Inflammation/Immunology Cancer
Roquinimex (Linomide) is an orally active immunomodulator with antineoplastic, anti-inflammatory, and antiangiogenic activity. Roquinimex suppresses TH1 lymphocyte cytokines (IL-2, IFN-γ), promotes TH2 lymphocyte cytokines (IL-4, IL-10), increases NK cell, activated monocyte, and T cell activity. Roquinimex blocks macrophage TNF-α production and suppresses IL-1/IL-6 secretion. Roquinimex exhibits in vivo antitumour activity, suppresses rodent autoimmune disease signs, and ameliorates murine colitis and psoriasis. Roquinimex can be used for the research of leukemia, inflammatory bowel disease, multiple sclerosis, and psoriasis .

HY-120508

Pivanex AN-9; Pivalyloxymethyl butyrate	HDAC Bcr-Abl Apoptosis	Inflammation/Immunology Cancer
Pivanex (AN-9), a derivative of Butyric acid, is an orally active HDAC inhibitor. Pivanex down-regulates bcr-abl protein and enhances apoptosis. Pivanex has antimetastic and antiangiogenic properties .

HY-128571

FLT3-IN-4	FLT3	Cancer
FLT3-IN-4 is a potent and orally effective Fms-like tyrosine receptor kinase 3 (FLT3; IC₅₀=7 nM) inhibitor for treating acute myelogenous leukemia .

HY-178007

CDK2 degrader 8	CDK	Cancer
CDK2 degrader 8 (Compound1) is a CDK2 degrader. CDK2 degrader 8 shows potential anti-tumor activity by targeting CDK2. CDK2 degrader 8 can be used for the study of solid tumors (breast cancer, triple negative breast cancer, ovarian serous cystadenocarcinoma) and liquid tumors (diffuse large B-cell lymphoma, acute myelogenous leukemia) associated with abnormal CDK2 function .

HY-16445A

CNDAC	Nucleoside Antimetabolite/Analog Drug Metabolite Apoptosis DNA/RNA Synthesis	Cancer
CNDAC is a metabolite of the orally active agent Sapacitabine (HY-16445), and a nucleoside analog. CNDAC induces DNA damage and apoptosis .

HY-112852A

TL02-59 dihydrochloride	Src Apoptosis	Cancer
TL02-59 dihydrochloride is an orally active, selective Src-family kinase Fgr inhibitor with an IC₅₀ of 0.03 nM. TL02-59 dihydrochloride inhibits Lyn and Hck with IC₅₀s of 0.1 nM and 160 nM, respectively. TL02-59 dihydrochloride potently suppresses acute myelogenous leukemia (AML) cell growth .

HY-10202B

Tandutinib sulfate	FLT3 c-Kit PDGFR Apoptosis	Cancer
Tandutinib (MLN518) sulfate is a potent and selective inhibitor of the FLT3 with an IC₅₀ of 0.22 μM, and also inhibits c-Kit and PDGFR with IC₅₀s of 0.17 μM and 0.20 μM, respectively. Tandutinib sulfate can be used for acute myelogenous leukemia (AML) . Tandutinib sulfate has the ability to cross the blood-brain barrier .

HY-145723C

MAX-40279 hemiadipate 1 Publications Verification	FLT3 FGFR	Inflammation/Immunology Cancer
MAX-40279 hemiadipate is a dual and orally active inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hemiadipate is also effective against the FLT3 mutants such as FLT3 ^D835Y, suggesting that it can overcome resistance to Quizartinib (HY-13001) and Sorafenib (HY-10201). MAX-40279 hemiadipate inhibits NDRG1 phosphorylation at Ser330 and suppresses endothelial-to-mesenchymal transition (EndMT). MAX-40279 hemiadipate can be used for the research of acute myelogenous leukemia (AML) .

HY-10202R

Tandutinib (Standard) MLN518 (Standard); CT53518 (Standard)	Reference Standards FLT3 c-Kit PDGFR Apoptosis	Cancer
Tandutinib (Standard) is the analytical standard of Tandutinib. This product is intended for research and analytical applications. Tandutinib (MLN518) is a potent and selective inhibitor of the FLT3 with an IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50s of 0.17 μM and 0.20 μM, respectively. Tandutinib can be used for acute myelogenous leukemia (AML) . Tandutinib has the ability to cross the blood-brain barrier .

HY-10202AR

Tandutinib hydrochloride (Standard) MLN518 hydrochloride (Standard); CT53518 hydrochloride (Standard)	Reference Standards FLT3 c-Kit PDGFR Apoptosis	Cancer
Tandutinib (hydrochloride) (Standard) is the analytical standard of Tandutinib (hydrochloride). This product is intended for research and analytical applications. Tandutinib hydrochloride (MLN518 hydrochloride) is a potent and selective inhibitor of the FLT3 with an IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50s of 0.17 μM and 0.20 μM, respectively. Tandutinib hydrochloride can be used for acute myelogenous leukemia (AML) . Tandutinib hydrochloride has the ability to cross the blood-brain barrier .

HY-163406

PDE1-IN-6	Phosphatase Apoptosis	Cancer
PDE1-IN-6 (compound 6c) is a selectivity PDE1 inhibitor with the IC₅₀ of 7.5 nM. PDE1-IN-6 significantly inhibits the proliferation and induced cell apoptosis in Acute myelogenous leukemia cells .

HY-149031

DHODH-IN-22	Dihydroorotate Dehydrogenase	Cancer
DHODH-IN-22 is a potent, selective and orally active dihydroorotate dehydrogenase (DHODH) inhibitor with an IC₅₀ value of 0.3 nM. DHODH-IN-22 can be used for researching acute myelogenous leukemia (AML) .

HY-144371

DHODH-IN-20	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Inflammation/Immunology Cancer
DHODH-IN-20 (Compound 133) is a potent inhibitor of DHODH. DHODH is present in the inner membrane of human mitochondria and is an iron-containing flavin-dependent enzyme. DHODH-IN-20 inhibits tumor growth. DHODH-IN-20 has the potential for the research of acute myelogenous leukemia .

HY-145723A

MAX-40279 hydrochloride	FLT3 FGFR	Inflammation/Immunology Cancer
MAX-40279 hydrochloride is a dual and orally active inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hydrochloride is also effective against the FLT3 mutants such as FLT3 ^D835Y, suggesting that it can overcome resistance to Quizartinib (HY-13001) and Sorafenib (HY-10201). MAX-40279 hydrochloride inhibits NDRG1 phosphorylation at Ser330 and suppresses endothelial-to-mesenchymal transition (EndMT). MAX-40279 hydrochloride can be used for the research of acute myelogenous leukemia (AML) .

HY-145723B

MAX-40279 hemifumarate 1 Publications Verification	FLT3 FGFR	Inflammation/Immunology Cancer
MAX-40279 hemifumarate is a dual and orally active inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hemifumarate is also effective against the FLT3 mutants such as FLT3 ^D835Y, suggesting that it can overcome resistance to Quizartinib (HY-13001) and Sorafenib (HY-10201). MAX-40279 hemifumarate inhibits NDRG1 phosphorylation at Ser330 and suppresses endothelial-to-mesenchymal transition (EndMT). MAX-40279 hemifumarate can be used for the research of acute myelogenous leukemia (AML) .

HY-50671R

Zosuquidar trihydrochloride (Standard) RS 33295-198 trihydrochloride (Standard); LY-335979 trihydrochloride (Standard)	Reference Standards P-glycoprotein	Cancer
Zosuquidar (trihydrochloride) (Standard) is the analytical standard of Zosuquidar (trihydrochloride). This product is intended for research and analytical applications. Zosuquidar (LY335979) trihydrochloride is a P-glycoprotein (P-gp) inhibitor (K_i=59 nM). Zosuquidar trihydrochloride shows anti-tumor activities, and can be used in acute myelogenous leukemia (AML) research .

HY-161711

CBP/p300 ligand 5	Ligands for Target Protein for PROTAC	Cancer
CBP/p300 ligand 5 is the target protein ligand of XYD129 (HY-161710). CBP/p300 ligand 5 can be used to study the acute myelogenous leukemia .

HY-149735

BET-IN-20	Epigenetic Reader Domain Apoptosis	Cancer
BET-IN-20 (compound 10) is an inhibitor of BRD4 BD1 (IC₅₀=1.9 nM) with anticancer activity. BET-IN-20 can promote acute myeloid leukemia (AML) cell apoptosis and arrest the cell cycle in the G0/G1 phase. BET-IN-20 also inhibits c-Myc and CDK6 and enhances PARP cleavage .

HY-16445BR

CNDAC hydrochloride (Standard)	Reference Standards Nucleoside Antimetabolite/Analog Drug Metabolite Apoptosis DNA/RNA Synthesis	Cancer
Dioscin (Standard) is the analytical standard of Dioscin. This product is intended for research and analytical applications. Dioscin (CCRIS 4123; Collettiside III) is a natural plant-derived steroidal saponin that has good anti-cancer activity against a variety of cancer cells. Dioscin causes DNA damage and induces apoptosis in HeLa and SiHa cells. Dioscin regulates ROS-mediated DNA damage and mitochondrial signaling pathways, exerting anticancer activity .

HY-112654A

GCN2iB acetate	Eukaryotic Initiation Factor (eIF) Glutathione Peroxidase	Cardiovascular Disease Metabolic Disease Cancer
GCN2iB acetate is an ATP-competitive, selective GCN2 inhibitor with an IC₅₀ of 2.4 nM. GCN2iB acetate inhibits the activation of the GCN2 pathway and upregulates GPX4. GCN2iB acetate enhances the anticancer effect of ASNase against acute lymphoblastic leukemia. GCN2iB acetate increases left ventricular ejection fraction, while reducing fasting blood glucose and myocardial fibrosis. GCN2iB acetate can be used in research related to acute lymphoblastic leukemia, acute myeloid leukemia and diabetic cardiomyopathy .

HY-181710

LASSBio-2337	mTOR PI3K	Cancer
LASSBio-2337 is a dual pan-PI3K/mTOR inhibitor with an mTOR IC₅₀ of 5.8 μM.LASSBio-2337 functionally modulates mTOR and all PI3K isoforms.LASSBio-2337 acts as a cytotoxic agent in leukemia cells, including multidrug-resistant populations.LASSBio-2337 spares nontumor human peripheral blood mononuclear cells.LASSBio-2337 displays moderate PAMPA-GIT permeability.LASSBio-2337 shows low metabolic stability in rat liver microsomes.LASSBio-2337 is aqueous insoluble.LASSBio-2337 can be used for the research of acute lymphoblastic leukemia, chronic myelogenous leukemia, breast cancer .

HY-112852S

TL02-59-d5	Isotope-Labeled Compounds Src Apoptosis	Cancer
TL02-59-d₅ is the deuterium labeled TL02-59 (HY-112852). TL02-59 is an orally active, selective Src-family kinase Fgr inhibitor with an ICC₅₀ of 0.03 nM. TL02-59 inhibits Lyn and Hck with ICC₅₀s of 0.1 nM and 160 nM, respectively. TL02-59 potently suppresses acute myelogenous leukemia (AML) cell growth.

HY-180836

DIX-01	Molecular Glues IKZF Family Apoptosis	Cancer
DIX-01 is a molecular gel degrader that can simultaneously induce the degradation of IKZF1/3 and GSPT1 mediated by CRBN. Its DC₅₀ values are: IKZF1 (19.80 nM), IKZF3 (45.31 nM), and GSPT1 (120.1 nM). DIX-01 exhibits nanomolar-level potent anti-proliferative activity in various cancer cell lines. DIX-01 induces apoptosis in MV4-11 cells and significantly inhibits the growth of leukemia cells in zebrafish. DIX-01 can be used for the study of malignant hematological tumors .

HY-13743R

Roquinimex (Standard) Linomide (Standard); FCF89 (Standard); ABR212616 (Standard)	Reference Standards TNF Receptor Interleukin Related IFNAR	Inflammation/Immunology
Roquinimex (Standard) is the analytical standard of Roquinimex (HY-13743). Roquinimex (Linomide) is an orally active immunomodulator with antineoplastic, anti-inflammatory, and antiangiogenic activity. Roquinimex suppresses TH1 lymphocyte cytokines (IL-2, IFN-γ), promotes TH2 lymphocyte cytokines (IL-4, IL-10), increases NK cell, activated monocyte, and T cell activity. Roquinimex blocks macrophage TNF-α production and suppresses IL-1/IL-6 secretion. Roquinimex exhibits in vivo antitumour activity, suppresses rodent autoimmune disease signs, and ameliorates murine colitis and psoriasis. Roquinimex can be used for the research of leukemia, inflammatory bowel disease, multiple sclerosis, and psoriasis .

HY-182349

Bax activator-2	Bcl-2 Family	Cancer
Bax activator-2 (compound 27c) is a pro-apoptotic agent targeting BAX, with an IC₅₀ of 0.30 μmol/L against human BAX. Bax activator-2 binds to the trigger site of BAX and induces its conformational change. Bax activator-2 induces mitochondrial depolarization, cytochrome c release, caspase-3/9 cleavage and PARP cleavage, thereby initiating apoptosis. Bax activator-2 exhibits cytotoxicity against various cancer cell lines, shows reduced cytotoxicity in BAX-knockout A549 cells, and has low cytotoxicity against non-cancerous cell lines. Bax activator-2 can be used in studies related to acute myeloid leukemia and solid tumors .

Cat. No.	Product Name	Target	Research Area

HY-P4122

TAT (47-57), FAM-labeled	HIV	Others
TAT (47-57), FAM-labeled is a 5(6)-Carboxyfluorescein (HY-15940)-labeled TAT (HY-P0281). TAT (YGRKKRRQRRR) is derived from the transactivator of transcription (TAT) of human immunodeficiency virus-1 (HIV-1) and is a cell-penetrating peptide .

Cat. No.	Product Name	Chemical Structure

HY-112852S

TL02-59-d5
TL02-59-d₅ is the deuterium labeled TL02-59 (HY-112852). TL02-59 is an orally active, selective Src-family kinase Fgr inhibitor with an ICC₅₀ of 0.03 nM. TL02-59 inhibits Lyn and Hck with ICC₅₀s of 0.1 nM and 160 nM, respectively. TL02-59 potently suppresses acute myelogenous leukemia (AML) cell growth.

Cat. No.	Product Name		Classification

HY-150725

ODN 1585		CpG ODNs
ODN 1585 is a potent inducer of IFN and TNFα production. ODN 1585 is a potent stimulator of NK (natural killer) function. ODN 1585 increases CD8+ T-cell function, including the CD8+ T cell-mediated production of IFN-γ. ODN 1585 induces regression of established melanomas in mice. ODN 1585 can confer complete protection against malaria in mice. ODN 1585 can be used for acute myelogenous leukemia (AML) and malaria research. ODN 1585 can be used as a vaccine adjuvant .

HY-150725C

ODN 1585 sodium		CpG ODNs
ODN 1585 sodium is a potent inducer of IFN and TNFα production. ODN 1585 sodium is a potent stimulator of NK (natural killer) function. ODN 1585 sodium increases CD8+ T-cell function, including the CD8+ T cell-mediated production of IFN-γ. ODN 1585 sodium induces regression of established melanomas in mice. ODN 1585 sodium can confer complete protection against malaria in mice. ODN 1585 sodium can be used for acute myelogenous leukemia (AML) and malaria research. ODN 1585 sodium can be used as a vaccine adjuvant .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: